Sustained Short Pressure Detected
ImmunityBio (IBRX) is currently exhibiting significant short-selling pressure, as evidenced by its presence on the FINRA Reg-SHO threshold list. This designation indicates that the stock has experienced sustained settlement-level failures-to-deliver for at least five consecutive trading days. Data from Tapeboard confirms that IBRX has maintained a high short-volume ratio, with recent metrics showing a 61% short-volume ratio and a 30.5% short interest as a percentage of float.
Market Implications
The presence of a stock on the threshold list is a critical signal for market participants, as it suggests that short sellers are struggling to locate shares to settle their positions. With a borrow fee currently hovering around 0.6% and a days-to-cover ratio of 7.7, the setup indicates a potential for increased volatility. Investors should monitor the daily short volume flow closely, as the combination of high short volume and settlement failures often precedes significant price action.
Key Takeaways
- IBRX is flagged on the FINRA Reg-SHO threshold list for 5+ consecutive days.
- Short interest as a percentage of float is currently 30.5%.
- The stock shows a high short-volume ratio of 61%.
- Settlement-level failures indicate potential difficulty in locating shares for delivery.
The Bottom Line
IBRX is currently under heavy short-selling pressure. The sustained failure-to-deliver status makes this a high-risk, high-reward ticker to watch for potential squeeze dynamics.
Signal data sourced from Tapeboard. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.